From King Faisal Cardiac Center (Alzahrani, Mufti, Al Rahimi, Al Kashkari), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah; from the Department of Radiology (Althobaiti), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, from King Abdullah International Medical Research Center, (Alzahrani, Mufti, Alswat, Altirkistani, Aljehani, Jazzar, Alutaibi, Abushouk, Rahimi, Kashkari, Althobaiti), Jeddah, Kingdom of Saudi Arabia; from the College of Medicine (Alzahrani, Mufti, Alsawat, Altirkistani, Aljehani, Jazzar, Alutaibi, Abushouk, Al Rahimi, Al Kashkari, Althobaiti), King Saud Bin Aldulaziz University for Health Sciences, Jeddah, Kingdom of Saudi Arabia.
Saudi Med J. 2023 Apr;44(4):373-378. doi: 10.15537/smj.2023.44.4.20220133.
To investigate the influence of viability assessment in the management of patients with ischemic cardiomyopathy (ICM).
This retrospective cohort study included all patients with ICM with moderate to severely reduced left ventricular ejection fraction (LVEF) who underwent viability assessment using cardiac magnetic resonance imaging (MRI) and echocardiogram as modalities of imaging. In addition, LVEF, modality of choice, and treatment plans were all extracted as main variables from the electronic database. One hundred 6 patients who met the inclusion criteria from December 2014 to December 2019 were included.
Posttreatment LVEF improved by 5% in the viable group compared to the nonviable group (=0.016). Regardless of the treatment received, 6 (8.8%) patients in the viable group died due to cardiac causes after an 18-month follow-up period; in contrast, 7 (18.4%) patients died due to cardiac causes in the nonviable group. However, despite that difference, this was not statistically significant (=0.153). Medical therapy alone was observed in 32 (84.2%) patients in the nonviable group compared to 32 (47.1%) in the viable group (<0.001). Although the reduction in hospitalization for cardiac reasons was not statistically significant, the viable arm had 50% fewer hospitalizations than the nonviable arm (=0.051).
Patients with viable myocardium had better outcomes in which LVEF significantly improved posttreatment. Additionally, there was a reduction in the number of hospitalizations for cardiac reasons in the viable group compared to the nonviable group, even though the difference was not statistically significant. However, further studies with a larger number of patients are needed to determine a definite conclusion.
探讨存活心肌评估对缺血性心肌病(ICM)患者管理的影响。
本回顾性队列研究纳入了所有接受心脏磁共振成像(MRI)和超声心动图作为影像学检查手段评估存活心肌的中重度左心室射血分数(LVEF)降低的 ICM 患者。此外,还从电子数据库中提取了 LVEF、首选模式和治疗计划等主要变量。纳入了 2014 年 12 月至 2019 年 12 月期间符合纳入标准的 106 例患者。
与非存活组相比,存活组治疗后的 LVEF 提高了 5%(=0.016)。无论接受何种治疗,存活组在 18 个月的随访期间有 6(8.8%)例患者因心脏原因死亡;而在非存活组,有 7(18.4%)例患者因心脏原因死亡。然而,尽管存在这种差异,但差异无统计学意义(=0.153)。非存活组中仅接受药物治疗的患者有 32 例(84.2%),而存活组中仅有 32 例(47.1%)(<0.001)。尽管因心脏原因住院的减少无统计学意义,但存活组的住院次数比非存活组减少了 50%(=0.051)。
存活心肌患者的 LVEF 在治疗后显著改善,预后更好。此外,与非存活组相比,存活组因心脏原因住院的次数减少,尽管差异无统计学意义。然而,需要进一步开展更多患者的研究,以确定明确的结论。